Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alexanian

Showing results (141-150 of 196) with videos related to

Pageof 20
Sort By:
Investigational New Drugs|May 10, 2023
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growthArshak R Alexanian, Heidi Marie Stoellinger, Virginea de Araujo Farias, et al.
Radiology|November 1, 1994
Multiple myeloma: MR patterns of response to treatmentL A Moulopoulos, M A Dimopoulos, R Alexanian, et al.
Bone Marrow Transplantation|December 10, 2013
Value of novel agents and intensive therapy for patients with multiple myelomaR Alexanian, M Wang, K Delasalle, et al.
Restorative Neurology and Neuroscience|January 7, 2011
Survival of neurally induced mesenchymal cells may determine degree of motor recovery in injured spinal cord ratsArshak R Alexanian, Wai-Meng Kwok, Danijel Pravdic, et al.
Bone Marrow Transplantation|July 5, 2001
Impact of complete remission with intensive therapy in patients with responsive multiple myelomaR Alexanian, D Weber, S Giralt, et al.
American Journal of Hematology|September 1, 1988
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemiaJ R Quesada, R Alexanian, R Kurzrock, et al.
Cellular Reprogramming|July 2, 2011
Feline bone marrow-derived mesenchymal stem cells express several pluripotent and neural markers and easily turn into neural-like cells by manipulation with chromatin modifying agents and neural inducing factorsZhiying Zhang, Dennis J Maiman, Shekar N Kurpad, et al.
Cancer Treatment Reports|June 1, 1982
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ Bonnet, R Alexanian, S Salmon, et al.
Leukemia & Lymphoma|May 1, 1994
Intensive sequential therapy for VAD-resistant multiple myelomaM A Dimopoulos, D M Weber, J Hester, et al.
Blood|December 1, 1988
Prognostic factors with high-dose melphalan for refractory multiple myelomaB Barlogie, R Alexanian, L Smallwood, et al.
Pageof 20

Showing results (141-150 of 196) with videos related to

Sort By:
Pageof 20
Investigational New Drugs|May 10, 2023
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growthArshak R Alexanian, Heidi Marie Stoellinger, Virginea de Araujo Farias, et al.
Radiology|November 1, 1994
Multiple myeloma: MR patterns of response to treatmentL A Moulopoulos, M A Dimopoulos, R Alexanian, et al.
Bone Marrow Transplantation|December 10, 2013
Value of novel agents and intensive therapy for patients with multiple myelomaR Alexanian, M Wang, K Delasalle, et al.
Restorative Neurology and Neuroscience|January 7, 2011
Survival of neurally induced mesenchymal cells may determine degree of motor recovery in injured spinal cord ratsArshak R Alexanian, Wai-Meng Kwok, Danijel Pravdic, et al.
Bone Marrow Transplantation|July 5, 2001
Impact of complete remission with intensive therapy in patients with responsive multiple myelomaR Alexanian, D Weber, S Giralt, et al.
American Journal of Hematology|September 1, 1988
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemiaJ R Quesada, R Alexanian, R Kurzrock, et al.
Cellular Reprogramming|July 2, 2011
Feline bone marrow-derived mesenchymal stem cells express several pluripotent and neural markers and easily turn into neural-like cells by manipulation with chromatin modifying agents and neural inducing factorsZhiying Zhang, Dennis J Maiman, Shekar N Kurpad, et al.
Cancer Treatment Reports|June 1, 1982
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ Bonnet, R Alexanian, S Salmon, et al.
Leukemia & Lymphoma|May 1, 1994
Intensive sequential therapy for VAD-resistant multiple myelomaM A Dimopoulos, D M Weber, J Hester, et al.
Blood|December 1, 1988
Prognostic factors with high-dose melphalan for refractory multiple myelomaB Barlogie, R Alexanian, L Smallwood, et al.
Pageof 20